Hero Image

Investor Relations

Investor Relations

Investor Relations

Elevating Human Health

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs.

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs.

As Featured In

Model Medicines

Innovating at the Intersection of Data Science, Biology and Drug Development

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs.

With GALILEO™, we've discovered 192 compounds and advanced 67 assets in cellular models of disease across 12 therapeutic targets for multiple areas of biology. Our data was validated by preeminent researchers and scientists at premier academic and corporate laboratories.

The company was founded in La Jolla, CA in 2019 to deliver on the promise of AI-Drug discovery.

AssetS

67

Targets

12

Hit Rate

66.7%

Preclinical Lead assets

2

Investors

Invested in Our Success

We’re backed by leading, multi-stage investors with significant expertise and sophistication in the Bio-IT/pharma space.

Pre-Prints & Papers

Sep 10, 2024

Paper

AI Hit Rates and Novelty

Sep 10, 2024

Paper

AI Hit Rates and Novelty

Sep 10, 2024

Paper

AI Hit Rates and Novelty

Apr 8, 2024

Pre-Print

Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor

Apr 8, 2024

Pre-Print

Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor

Apr 8, 2024

Pre-Print

Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor

Mar 28, 2024

Pre-Print

Model Medicines Publishes Groundbreaking Preprint on AI-Driven Drug Discovery

Mar 28, 2024

Pre-Print

Model Medicines Publishes Groundbreaking Preprint on AI-Driven Drug Discovery

Mar 28, 2024

Pre-Print

Model Medicines Publishes Groundbreaking Preprint on AI-Driven Drug Discovery

Mar 11, 2024

Paper

Dissimilar, Drug-Like, Novel Chemical Entities (DDL-NCEs); Using Multimodal Generative AI

Mar 11, 2024

Paper

Dissimilar, Drug-Like, Novel Chemical Entities (DDL-NCEs); Using Multimodal Generative AI

Mar 11, 2024

Paper

Dissimilar, Drug-Like, Novel Chemical Entities (DDL-NCEs); Using Multimodal Generative AI

Dec 19, 2023

Paper

Biochemistry's Hidden Matrix: Atomic Constellations

Dec 19, 2023

Paper

Biochemistry's Hidden Matrix: Atomic Constellations

Dec 19, 2023

Paper

Biochemistry's Hidden Matrix: Atomic Constellations

Sep 27, 2023

Paper

Vanity Metrics & Black Boxes ≠Therapeutics

Sep 27, 2023

Paper

Vanity Metrics & Black Boxes ≠Therapeutics

Sep 27, 2023

Paper

Vanity Metrics & Black Boxes ≠Therapeutics

Sep 12, 2023

Paper

Breaking the Data Dogma

Sep 12, 2023

Paper

Breaking the Data Dogma

Sep 12, 2023

Paper

Breaking the Data Dogma

Mar 20, 2023

Paper

Overcoming PAINS in AI Drug Discovery

Mar 20, 2023

Paper

Overcoming PAINS in AI Drug Discovery

Mar 20, 2023

Paper

Overcoming PAINS in AI Drug Discovery

Load More

Load More

Load More

Events

Dec 3, 2024

Events

Model Medicines to Keynote CPHI Middle East

Dec 3, 2024

Events

Model Medicines to Keynote CPHI Middle East

Dec 3, 2024

Events

Model Medicines to Keynote CPHI Middle East

Apr 17, 2024

Events

Model Medicines to Participate in Upcoming TSX Investor Event

Apr 17, 2024

Events

Model Medicines to Participate in Upcoming TSX Investor Event

Apr 17, 2024

Events

Model Medicines to Participate in Upcoming TSX Investor Event

Load More

Load More

Load More

Announcements

A Guide to Streamlining Your Business

Jun 5, 2024

Announcement

Model Medicines Announces Nomination of Preclinical Candidate, MDL-4101, Targeting BRD4 for the Treatment of Thyroid Cancer

A Guide to Streamlining Your Business

Jun 5, 2024

Announcement

Model Medicines Announces Nomination of Preclinical Candidate, MDL-4101, Targeting BRD4 for the Treatment of Thyroid Cancer

A Guide to Streamlining Your Business

Jun 5, 2024

Announcement

Model Medicines Announces Nomination of Preclinical Candidate, MDL-4101, Targeting BRD4 for the Treatment of Thyroid Cancer

Apr 24, 2024

Announcement

Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor

Apr 24, 2024

Announcement

Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor

Apr 24, 2024

Announcement

Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor

Load More

Load More

Load More